{
  "timestamp": "2026-02-11T06:45:00.000Z",
  "scorer": "opus-4.6-interactive",
  "source_recording": "record-2026-02-11-0613.json",
  "cycle": 7,
  "cycle_description": "IDEA re-embedding + cancer type normalization + HPV ctDNA retrieval fix",
  "fixes_applied": [
    "IDEA (ID 381) summary rewritten with query-aligned clinical terms, re-embedded",
    "Cancer type normalization mapping added (head and neck → head_neck, oropharyngeal → head_neck, etc.)",
    "Deployed to Railway with updated server.js"
  ],
  "summary": {
    "averageScore": 9.0,
    "maxScore": 10,
    "passRate": "10/10",
    "passPercentage": 100,
    "failing": 0,
    "errors": 0,
    "notes": "Q8 BREAKTHROUGH: 8→10, HPV ctDNA distinction now present ('viral DNA sequences integrated into tumor cells, offering a distinct analyte'). Q3 DYNAMIC present again. Q10 regressed 10→8 (IMvigor011 results hedged vs C6 where PMID was cited). IDEA still not surfacing for Q2 despite re-embedding. Cancer type normalization confirmed working for H&N."
  },
  "dimensionAverages": {
    "accuracy": 1.9,
    "completeness": 1.8,
    "evidence_quality": 1.3,
    "automation_bias_mitigation": 1.0,
    "criterion3_nondirective": 2.0,
    "criterion4_transparency": 1.0
  },
  "comparison_to_c6": {
    "passRate": "10/10 → 10/10 (stable)",
    "avgScore": "9.1 → 9.0 (down 0.1, within noise)",
    "improvements": ["Q8: 8→10 (HPV ctDNA distinction + performance data!)"],
    "regressions": ["Q1: 10→9 (lost DYNAMIC from C6 re-recording)", "Q10: 10→8 (IMvigor011 results hedged, was explicit in C6)"],
    "stable": ["Q2(8), Q3(9), Q4(8), Q5(9), Q6(10), Q7(9), Q9(10)"]
  },
  "score_progression": {
    "original": { "passRate": "80%", "avg": 8.6 },
    "c1b": { "passRate": "90%", "avg": 8.7 },
    "c2": { "passRate": "90%", "avg": 8.7 },
    "c3": { "passRate": "100%", "avg": 8.9 },
    "c4": { "passRate": "90%", "avg": 8.8 },
    "c5": { "passRate": "90%", "avg": 8.6 },
    "c6": { "passRate": "100%", "avg": 9.1 },
    "c7": { "passRate": "100%", "avg": 9.0 }
  },
  "results": [
    {
      "id": 1,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 6
      },
      "total": 9,
      "pass": true,
      "summary": "DYNAMIC missing (was present in C6 re-recording). CIRCULATE-US, GALAXY, Signatera, FOLFOXIRI all present. Solid but inconsistent DYNAMIC retrieval."
    },
    {
      "id": 2,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 1,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 5
      },
      "total": 8,
      "pass": true,
      "summary": "C3 fixed (stable). DYNAMIC and IDEA still missing despite IDEA re-embedding. Three good options with practical monitoring variant. GALAXY only named trial."
    },
    {
      "id": 3,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 6
      },
      "total": 9,
      "pass": true,
      "summary": "DYNAMIC present and correctly contextualized with ESMO level III. GALAXY HRs accurate. Stable at 9."
    },
    {
      "id": 4,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 5
      },
      "total": 8,
      "pass": true,
      "summary": "New trial references (ARTEMIS, PERSEVERE, ZEST, BRCA) but missing immunotherapy angle entirely — no pembrolizumab, KEYNOTE-522, or checkpoint inhibitor discussion."
    },
    {
      "id": 5,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 6
      },
      "total": 9,
      "pass": true,
      "summary": "Lead time mentioned. ESR1/CDK4/6 inhibitor context practical. Missing Parsons et al. and specific median lead time number."
    },
    {
      "id": 6,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 2,
        "automation_bias_mitigation": 1,
        "subtotal": 7
      },
      "total": 10,
      "pass": true,
      "summary": "Outstanding. ADAURA OS benefit correctly framed. Cross-indication properly caveated. Consistent 10/10."
    },
    {
      "id": 7,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 6
      },
      "total": 9,
      "pass": true,
      "summary": "DYNAMIC missing this cycle. NCCN/ESMO well-cited. Practical options for monitoring schedule. Stable at 9."
    },
    {
      "id": 8,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 2,
        "automation_bias_mitigation": 1,
        "subtotal": 7
      },
      "total": 10,
      "pass": true,
      "summary": "BREAKTHROUGH: HPV ctDNA as distinct analyte from somatic mutation-based MRD now present. NavDx performance data (90.4% sensitivity, 98.6% specificity, 4-month lead time, >95% NPV). De-intensification trials mentioned. All shouldMentions found. Cancer type normalization fix confirmed working."
    },
    {
      "id": 9,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 2,
        "automation_bias_mitigation": 1,
        "subtotal": 7
      },
      "total": 10,
      "pass": true,
      "summary": "Excellent. ALTAIR with specific HR/DFS data. RAPID-1 terminated. GALAXY. NCT number. Treatment of molecular recurrence framing is sophisticated."
    },
    {
      "id": 10,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 5
      },
      "total": 8,
      "pass": true,
      "summary": "Regressed from C6 (10→8). IMvigor011 identified but results hedged ('not available'). In C6, PMID 41124204 was cited with positive results. RAG inconsistency. Missing CheckMate 274."
    }
  ]
}
